Literature DB >> 23591717

Angioedema with normal C1q and C1 inhibitor: an atypical presentation of Waldenström macroglobulinemia.

Anas Khanfar1, Anita Trikha, Rana Bonds, Bagi Jana.   

Abstract

Angioedema is a recurrent, non-pitting, non-pruritic, transitory swelling due to transient increase of endothelial permeability in the capillaries of the deep cutaneous and mucosal layers. Angioedema is generally categorized based on etiology, and characteristic lab findings are associated with each category. Cases of acquired angioedema associated with myeloproliferative disorders have been described in the literature, but these have been associated with a characteristic low C1q, a defining laboratory finding in acquired angioedema. Here we present a case of 68-year-old female with acquired angioedema that was not associated with low C1q, but was found to have Waldenström disease. Her angioedema responded dramatically to combination therapy consisting of bortezomib, rituximab, and dexamethasone.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23591717     DOI: 10.1007/s12185-013-1330-z

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  8 in total

1.  Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling.

Authors:  O Tournilhac; D D Santos; L Xu; J Kutok; Y-T Tai; S Le Gouill; L Catley; Z Hunter; A R Branagan; J A Boyce; N Munshi; K C Anderson; S P Treon
Journal:  Ann Oncol       Date:  2006-06-20       Impact factor: 32.976

Review 2.  Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional management.

Authors:  Lorenza Chiara Zingale; Roberto Castelli; Andrea Zanichelli; Marco Cicardi
Journal:  Immunol Allergy Clin North Am       Date:  2006-11       Impact factor: 3.479

Review 3.  Clinical practice. Hereditary angioedema.

Authors:  Bruce L Zuraw
Journal:  N Engl J Med       Date:  2008-09-04       Impact factor: 91.245

4.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus F San-Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; William S Dalton; Anthony L Boral; Dixie L Esseltine; Jane B Porter; David Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

5.  Acquired C1-inhibitor deficiency: 7 patients treated with rituximab.

Authors:  Albanne Branellec; Laurence Bouillet; Nicolas Javaud; Arsène Mekinian; Isabelle Boccon-Gibod; Claire Blanchard-Delaunay; Eric Oksenhendler; Yann Ollivier; Bertrand Dunogué; Stephanie Amarger; Denise Ponard; Christian Drouet; Luc Mouthon; Michel Thomas; Olivier Fain
Journal:  J Clin Immunol       Date:  2012-04-20       Impact factor: 8.317

Review 6.  Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies.

Authors:  Marco Cicardi; Lorenza C Zingale; Emanuela Pappalardo; Anna Folcioni; Angelo Agostoni
Journal:  Medicine (Baltimore)       Date:  2003-07       Impact factor: 1.889

7.  Acquired angioedema.

Authors:  Marco Cicardi; Andrea Zanichelli
Journal:  Allergy Asthma Clin Immunol       Date:  2010-07-28       Impact factor: 3.406

8.  Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

Authors:  Steven P Treon; Leukothea Ioakimidis; Jacob D Soumerai; Christopher J Patterson; Patricia Sheehy; Marybeth Nelson; Michael Willen; Jeffrey Matous; John Mattern; Jakow G Diener; George P Keogh; Thomas J Myers; Andy Boral; Ann Birner; Dixie L Esseltine; Irene M Ghobrial
Journal:  J Clin Oncol       Date:  2009-06-08       Impact factor: 44.544

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.